Cytokinetics Interest Income from 2010 to 2026

CYTK Stock

USD 64.85 1.49 2.35%

Cytokinetics Interest Income yearly trend continues to be quite stable with very little volatility. Interest Income may rise above about 62.2 M this year. Interest Income is income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments. View All Fundamentals

Interest Income

First Reported

2019-03-31

Previous Quarter

13 M

Current Value

10.2 M

Quarterly Volatility

5.2 M

Covid

Interest Hikes

Check Cytokinetics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cytokinetics' main balance sheet or income statement drivers, such as Interest Expense of 104.5 M, Other Operating Expenses of 669.8 M or Research Development of 409.8 M, as well as many indicators such as Price To Sales Ratio of 269, Dividend Yield of 0.0 or Days Sales Outstanding of 299. Cytokinetics financial statements analysis is a perfect complement when working with Cytokinetics Valuation or Volatility modules.

Build AI portfolio with Cytokinetics Stock

Check out the analysis of Cytokinetics Correlation against competitors.

For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.

Historical Interest Income data for Cytokinetics serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Cytokinetics represents a compelling investment opportunity.

Latest Cytokinetics' Interest Income Growth Pattern

Below is the plot of the Interest Income of Cytokinetics over the last few years. It is income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments. Cytokinetics' Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cytokinetics' overall financial position and show how it may be relating to other accounts over time.

Interest Income

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Interest Income

Timeline

Cytokinetics Interest Income Regression Statistics

	Arithmetic Mean	13,432,083
	Geometric Mean	1,541,253
	Coefficient Of Variation	164.90
	Mean Deviation	17,089,303
	Median	2,602,000
	Standard Deviation	22,149,229
	Sample Variance	490.6T
	Range	62.1M
	R-Value	0.79
	Mean Square Error	200T
	R-Squared	0.62
	Significance	0.0002
	Slope	3,447,557
	Total Sum of Squares	7849.4T

Cytokinetics Interest Income History

	2026	62.2 M
	2025	59.3 M
	2024	51.5 M
	2023	26 M
	2022	11.3 M
	2021	331 K
	2020	5.3 M

Other Fundumenentals of Cytokinetics

Net Interest Income

Cytokinetics Interest Income component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Total Liab	Current Deferred Revenue	Accounts Payable	Long Term Debt	Net Receivables	Short Term Investments	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Net Tangible Assets	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Long Term Debt Total	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		-0.52	0.94	-0.95	0.98	0.91	0.93	0.88	0.33	0.99	1.0	0.95	-0.15	0.95	-0.6	0.81	0.85	0.92	0.39	0.82	0.86	0.98	0.92
Total Stockholder Equity	-0.52		-0.75	0.66	-0.66	-0.33	-0.55	-0.73	0.27	-0.56	-0.53	-0.67	0.04	-0.59	0.9	-0.47	-0.45	-0.26	-0.34	-0.57	-0.35	-0.53	-0.62
Net Debt	0.94	-0.75		-0.94	0.98	0.78	0.92	0.89	0.16	0.95	0.94	0.94	-0.16	0.95	-0.8	0.79	0.8	0.78	0.32	0.81	0.81	0.94	0.92
Retained Earnings	-0.95	0.66	-0.94		-0.97	-0.85	-0.9	-0.92	-0.24	-0.95	-0.95	-0.95	0.11	-0.91	0.69	-0.85	-0.83	-0.83	-0.44	-0.87	-0.81	-0.92	-0.94
Total Liab	0.98	-0.66	0.98	-0.97		0.87	0.92	0.93	0.23	0.98	0.98	0.97	-0.14	0.95	-0.72	0.8	0.83	0.86	0.41	0.83	0.82	0.97	0.93
Current Deferred Revenue	0.91	-0.33	0.78	-0.85	0.87		0.76	0.84	0.47	0.9	0.91	0.88	-0.08	0.8	-0.44	0.66	0.71	0.92	0.39	0.64	0.75	0.9	0.8
Accounts Payable	0.93	-0.55	0.92	-0.9	0.92	0.76		0.75	0.3	0.89	0.9	0.89	-0.18	0.98	-0.56	0.9	0.89	0.84	0.26	0.87	0.85	0.87	0.89
Long Term Debt	0.88	-0.73	0.89	-0.92	0.93	0.84	0.75		0.17	0.89	0.89	0.96	-0.12	0.82	-0.72	0.64	0.68	0.78	0.54	0.68	0.64	0.89	0.86
Net Receivables	0.33	0.27	0.16	-0.24	0.23	0.47	0.3	0.17		0.25	0.29	0.27	-0.05	0.34	0.29	0.31	0.33	0.52	-0.07	0.16	0.32	0.26	0.26
Short Term Investments	0.99	-0.56	0.95	-0.95	0.98	0.9	0.89	0.89	0.25		1.0	0.94	-0.13	0.91	-0.68	0.77	0.82	0.88	0.39	0.8	0.85	0.99	0.91
Total Current Assets	1.0	-0.53	0.94	-0.95	0.98	0.91	0.9	0.89	0.29	1.0		0.94	-0.14	0.92	-0.63	0.79	0.84	0.9	0.42	0.82	0.85	0.98	0.91
Short Term Debt	0.95	-0.67	0.94	-0.95	0.97	0.88	0.89	0.96	0.27	0.94	0.94		-0.17	0.93	-0.67	0.76	0.77	0.87	0.49	0.77	0.76	0.93	0.91
Common Stock	-0.15	0.04	-0.16	0.11	-0.14	-0.08	-0.18	-0.12	-0.05	-0.13	-0.14	-0.17		-0.19	0.0	-0.1	-0.26	-0.19	-0.13	0.03	-0.27	-0.21	-0.18
Property Plant Equipment	0.95	-0.59	0.95	-0.91	0.95	0.8	0.98	0.82	0.34	0.91	0.92	0.93	-0.19		-0.58	0.86	0.83	0.86	0.3	0.82	0.86	0.91	0.92
Net Tangible Assets	-0.6	0.9	-0.8	0.69	-0.72	-0.44	-0.56	-0.72	0.29	-0.68	-0.63	-0.67	0.0	-0.58		-0.44	-0.45	-0.33	-0.3	-0.57	-0.47	-0.65	-0.64
Capital Surpluse	0.81	-0.47	0.79	-0.85	0.8	0.66	0.9	0.64	0.31	0.77	0.79	0.76	-0.1	0.86	-0.44		0.85	0.73	0.29	0.95	0.87	0.73	0.91
Deferred Long Term Liab	0.85	-0.45	0.8	-0.83	0.83	0.71	0.89	0.68	0.33	0.82	0.84	0.77	-0.26	0.83	-0.45	0.85		0.8	0.14	0.87	0.74	0.78	0.79
Long Term Investments	0.92	-0.26	0.78	-0.83	0.86	0.92	0.84	0.78	0.52	0.88	0.9	0.87	-0.19	0.86	-0.33	0.73	0.8		0.31	0.69	0.8	0.88	0.82
Short Long Term Debt	0.39	-0.34	0.32	-0.44	0.41	0.39	0.26	0.54	-0.07	0.39	0.42	0.49	-0.13	0.3	-0.3	0.29	0.14	0.31		0.31	0.27	0.38	0.41
Long Term Debt Total	0.82	-0.57	0.81	-0.87	0.83	0.64	0.87	0.68	0.16	0.8	0.82	0.77	0.03	0.82	-0.57	0.95	0.87	0.69	0.31		0.79	0.73	0.87
Net Invested Capital	0.86	-0.35	0.81	-0.81	0.82	0.75	0.85	0.64	0.32	0.85	0.85	0.76	-0.27	0.86	-0.47	0.87	0.74	0.8	0.27	0.79		0.86	0.92
Net Working Capital	0.98	-0.53	0.94	-0.92	0.97	0.9	0.87	0.89	0.26	0.99	0.98	0.93	-0.21	0.91	-0.65	0.73	0.78	0.88	0.38	0.73	0.86		0.9
Capital Stock	0.92	-0.62	0.92	-0.94	0.93	0.8	0.89	0.86	0.26	0.91	0.91	0.91	-0.18	0.92	-0.64	0.91	0.79	0.82	0.41	0.87	0.92	0.9

Click cells to compare fundamentals

About Cytokinetics Financial Statements

Cytokinetics investors utilize fundamental indicators, such as Interest Income, to predict how Cytokinetics Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.

	Last Reported	Projected for Next Year
Interest Income	59.3 M	62.2 M
Net Interest Income	-31.5 M	-33.1 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet

When determining whether Cytokinetics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Cytokinetics Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Cytokinetics Stock. Highlighted below are key reports to facilitate an investment decision about Cytokinetics Stock:

How To Invest In Cytokinetics

Details

Is Cytokinetics Stock a good investment?

Details

What is Cytokinetics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Cytokinetics Correlation against competitors.

For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.

You can also try the CEOs Directory module to screen CEOs from public companies around the world.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. Projected growth potential of Cytokinetics fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Cytokinetics assessment requires weighing all these inputs, though not all factors influence outcomes equally.

Earnings Share

(6.30)

Revenue Per Share

0.733

Quarterly Revenue Growth

3.181

Return On Assets

(0.25)

Return On Equity

(5.72)

The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

It's important to distinguish between Cytokinetics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cytokinetics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Cytokinetics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Cytokinetics Interest Income from 2010 to 2026

Latest Cytokinetics' Interest Income Growth Pattern

Cytokinetics Interest Income Regression Statistics

Cytokinetics Interest Income History

Other Fundumenentals of Cytokinetics

Cytokinetics Interest Income component correlations

About Cytokinetics Financial Statements

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY